These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back

Published Wed, May 26 202110:20 AM EDTUpdated Wed, May 26 202112:42 PM EDT

Popular fund manger Cathie Wood's ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds' holdings. Shares of Wood's flagship ARK Innovation are down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood's top holdings, especially the high profile names like Tesla and Teladoc . Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet. All of Wood's other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year. However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names. CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts. The listed stocks are all holdings in one of Ark's core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks' average 12-month price target from analysts. Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity. Take a look at CNBC PRO's list here. Syros Pharmaceuticals and Compugen are two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy. Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months. "We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline," Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021. Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company "commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types." ARK Genomic Revolution purchased 36,907 shares of Codexis — a stock on CNBC PRO's list — worth about $728,500, based on the stock's price of $19.74 per share at Tuesday's closing. Surface Oncology , Berkeley Lights , Personalis , 1Life Healthcare, Silvergate Capital and Twilio also made CNBC PRO's list. Amazon also made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company's blowout earnings where sales surged 44%, analysts expect it to rally more than 30% in the next 12 months. ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare's closing price of $32.45 per share. Teledyne Technologies , Castle Biosciences , Ping An Healthcare and Technology, Niu Technologies , Guardant Health and Accolade also earned spots on CNBC PRO's list. Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet. Disclosure: CNBC parent Comcast in an investor in Accolade. — with reporting from CNBC's Michael Bloom.

Cathie Wood, chief executive officer and chief investment officer of ARK Investment Management LLC, speaks during the Sooner Than You Think conference in the Brooklyn borough of New York on Tuesday, Oct. 16, 2018.

Alex Flynn | Bloomberg | Getty Images

Popular fund manger Cathie Wood's ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds' holdings.

Shares of Wood's flagship ARK Innovation are down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood's top holdings, especially the high profile names like Tesla and Teladoc.

Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.

All of Wood's other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.

However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.

CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.